
Opinion|Videos|February 20, 2025
Reflections and Future Directions in R/R ALL
Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Logan: How do you partner or collaborate with your affiliated sites and/or community colleagues to ensure patients are being referred to CAR T-cell therapy?
Closing
- Dr. O’Dwyer: Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at ASH 2024. Let’s consider what opportunities/what we are looking forward to ahead in 2025.
- What accomplishments in R/R ALL are you most proud of? Which developments stand out as pivotal in shaping clinical practice?
- What are you most excited about in 2025? What areas are primed for significant progress? What do you hope to achieve in the coming year?
Advertisement
Related to this article

Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.

The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.

The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.

MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.

China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.

Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.

The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
5

